FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation (Adv. Sci. 29/2022)

Immunotherapy The FOXM1 inhibitor, thiostrepton, inhibits the expression of programmed death‐ligand 1 (PD‐L1) on the surface of cancer cells, allowing cytotoxic T cells to recognize cancer cells. Combination of thiostrepton and an immune checkpoint inhibitor significantly improves immunotherapy outc...

Descripción completa

Detalles Bibliográficos
Autores principales: Madhi, Hamadi, Lee, Jeon‐Soo, Choi, Young Eun, Li, Yan, Kim, Myoung Hee, Choi, Yongdoo, Goh, Sung‐Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Cover Picture
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561766/
http://dx.doi.org/10.1002/advs.202270183
_version_ 1784808018953633792
author Madhi, Hamadi
Lee, Jeon‐Soo
Choi, Young Eun
Li, Yan
Kim, Myoung Hee
Choi, Yongdoo
Goh, Sung‐Ho
author_facet Madhi, Hamadi
Lee, Jeon‐Soo
Choi, Young Eun
Li, Yan
Kim, Myoung Hee
Choi, Yongdoo
Goh, Sung‐Ho
author_sort Madhi, Hamadi
collection PubMed
description Immunotherapy The FOXM1 inhibitor, thiostrepton, inhibits the expression of programmed death‐ligand 1 (PD‐L1) on the surface of cancer cells, allowing cytotoxic T cells to recognize cancer cells. Combination of thiostrepton and an immune checkpoint inhibitor significantly improves immunotherapy outcomes in immune‐resistant lung tumors. More details can be found in article number 2202702 by Yongdoo Choi, Sung‐Ho Go, and co‐workers. [Image: see text]
format Online
Article
Text
id pubmed-9561766
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95617662022-10-16 FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation (Adv. Sci. 29/2022) Madhi, Hamadi Lee, Jeon‐Soo Choi, Young Eun Li, Yan Kim, Myoung Hee Choi, Yongdoo Goh, Sung‐Ho Adv Sci (Weinh) Cover Picture Immunotherapy The FOXM1 inhibitor, thiostrepton, inhibits the expression of programmed death‐ligand 1 (PD‐L1) on the surface of cancer cells, allowing cytotoxic T cells to recognize cancer cells. Combination of thiostrepton and an immune checkpoint inhibitor significantly improves immunotherapy outcomes in immune‐resistant lung tumors. More details can be found in article number 2202702 by Yongdoo Choi, Sung‐Ho Go, and co‐workers. [Image: see text] John Wiley and Sons Inc. 2022-10-14 /pmc/articles/PMC9561766/ http://dx.doi.org/10.1002/advs.202270183 Text en © 2022 Wiley‐VCH GmbH https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Cover Picture
Madhi, Hamadi
Lee, Jeon‐Soo
Choi, Young Eun
Li, Yan
Kim, Myoung Hee
Choi, Yongdoo
Goh, Sung‐Ho
FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation (Adv. Sci. 29/2022)
title FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation (Adv. Sci. 29/2022)
title_full FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation (Adv. Sci. 29/2022)
title_fullStr FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation (Adv. Sci. 29/2022)
title_full_unstemmed FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation (Adv. Sci. 29/2022)
title_short FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation (Adv. Sci. 29/2022)
title_sort foxm1 inhibition enhances the therapeutic outcome of lung cancer immunotherapy by modulating pd‐l1 expression and cell proliferation (adv. sci. 29/2022)
topic Cover Picture
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561766/
http://dx.doi.org/10.1002/advs.202270183
work_keys_str_mv AT madhihamadi foxm1inhibitionenhancesthetherapeuticoutcomeoflungcancerimmunotherapybymodulatingpdl1expressionandcellproliferationadvsci292022
AT leejeonsoo foxm1inhibitionenhancesthetherapeuticoutcomeoflungcancerimmunotherapybymodulatingpdl1expressionandcellproliferationadvsci292022
AT choiyoungeun foxm1inhibitionenhancesthetherapeuticoutcomeoflungcancerimmunotherapybymodulatingpdl1expressionandcellproliferationadvsci292022
AT liyan foxm1inhibitionenhancesthetherapeuticoutcomeoflungcancerimmunotherapybymodulatingpdl1expressionandcellproliferationadvsci292022
AT kimmyounghee foxm1inhibitionenhancesthetherapeuticoutcomeoflungcancerimmunotherapybymodulatingpdl1expressionandcellproliferationadvsci292022
AT choiyongdoo foxm1inhibitionenhancesthetherapeuticoutcomeoflungcancerimmunotherapybymodulatingpdl1expressionandcellproliferationadvsci292022
AT gohsungho foxm1inhibitionenhancesthetherapeuticoutcomeoflungcancerimmunotherapybymodulatingpdl1expressionandcellproliferationadvsci292022

Ejemplares similares